Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2558905 | 0.64 | ESR2 (0.35) | CYP11B2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL22751694 | 0.64 | CYP11B2 (0.43) | CYP11B2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1918668 | 0.62 | ALDH1A1 (0.35) | — | |
| SCHEMBL21831995 | 0.61 | CYP11B2 (0.35) | CYP11B2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL417593 | 0.60 | CYP11B2 (0.33) | CYP11B2 | |
| SCHEMBL23531092 | 0.56 | HTR2C (0.31) | — | |
| SCHEMBL20267373 | 0.56 | CYP11B2 (0.31) | CYP11B2 | |
| SCHEMBL4688167 | 0.55 | LMNA (0.48) | — | |
| SCHEMBL23530975 | 0.54 | NQO1 (0.35) | — | |
| SCHEMBL16877327 | 0.54 | TTR (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475262-B1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |
| US-10858342-B2 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858342-B2 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | REN, AGTR1, AGTR2 | CYP11B2 61/4885PIK3CD 869/4885PIK3CA 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.